1 unchanged sentence
Trading Plans
−Removed: On August 14, 2025 , Neha Krishnamohan , a member of our Board of Directors, entered into a Rule 10b5-1 trading plan , intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
−Removed: The plan provided for the potential sale of up to 1,232 shares of common stock held by Ms.
−Removed: Krishnamohan, as well as the potential exercise and sale of up to 39,272 options between November 12, 2025 and November 2, 2026 .
+Added: On March 13, 2026 , Howard G.
+Added: Welgus , M.D., a member of our Board of Directors , entered into a Rule 10b5-1 trading plan , intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: The plan provided for the potential exercise and sale of up to 49,134 options, as well as the potential sale of 7,609 shares resulting from RSUs vesting between June 15, 2026 and June 15, 2027 .
+Added: On March 13, 2026 , Todd Franklin Watanabe , our Chief Executive Officer , entered into a Rule 10b5-1 trading plan , intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: The plan provided for the potential sale of up to 325,000 shares of common stock held by Mr.
+Added: Watanabe between June 12, 2026 and June 11, 2027 .
+Added: Table of Content s
Number Description of Document Incorporated by Reference Form Date Number Filed/Furnished Herewith
7 unchanged sentences
S-1/A 1/21/20 4.2
+Added: Arcutis Biotherapeutics, Inc.
+Added: Amended and Restated 2022 Employment Inducement Incentive Plan.
31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
______________
−Removed: Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Regulation S-K, Item 601(b)(10) or certain schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Item 601(a)(5).
−Removed: Such omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
+Added: Registrant has omitted schedules (or similar attachments) pursuant to Item 601(a)(5) of Regulation S-K.
The Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.
+Added: # Indicates management contract or compensatory plan.
* The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Arcutis Biotherapeutics, Inc.
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
ARCUTIS BIOTHERAPEUTICS, INC.
−Removed: October 28, 2025 By:
+Added: May 06, 2026 By:
/s/ Todd Franklin Watanabe
2 unchanged sentences
(Principal Executive Officer)
−Removed: October 28, 2025 By:
+Added: May 06, 2026 By:
/s/ Latha Vairavan
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.